Localized Management of Vulvovaginal Candidiasis

Butoconazole Cream is commonly used across conditions presenting with acute episodes caused by the overgrowth of Candida yeast species. The primary therapeutic focus involves localized management used to address the fungal presence in the vagina. This application supports patients by addressing the source of infection, which may assist with managing the symptomatic manifestation.

---

This medication is generally used to treat uncomplicated VVC, helping to address core manifestations such as intense vaginal itching (pruritus), a burning sensation, and noticeable soreness. It is often applied during phases when discomfort becomes more noticeable, helping to ease the overall symptom burden.

“The treatment is relevant for managing symptom clusters that may become intense or disruptive.”

Applied when appropriate, it contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability by easing the impact of physical discomfort on routine activities.

Quick Fact: Relief for Inflammatory Discomfort Butoconazole is commonly used to help with symptoms related to inflammatory or irritative states of the vulvovaginal area, and provides supportive relief when physical discomfort interferes with routine activities.

Regulatory References

1. FDA-Approved Label via NIH DailyMed

Who Can and Cannot Use Butoconazole Cream?

The population eligibility for Butoconazole Cream is strictly defined by regulatory documents, outlining who may use the medicine and under what conditions.

Eligibility Status

Population Group	Regulatory Status
Non-Pregnant Adult Women	Use established as safe and effective.
Patients with Hypersensitivity	Contraindicated (Must not use due to allergy to any component).
Children/Pediatric Patients	Safety and effectiveness have not been established.
Pregnant Women	Conditional Use (Pregnancy Category C); use only if the potential benefit justifies the potential risk to the fetus.
Nursing Women	Caution must be exercised as excretion into human milk is unknown.

Use Restrictions and Cautions

Official labeling sets specific eligibility constraints based on the user's clinical status:

• Recurrent Infections: Women experiencing frequent or recurrent vaginal infections should be evaluated by a healthcare provider prior to use to rule out underlying serious conditions, such as Diabetes Mellitus or HIV risk.
• Organ Impairment: The official prescribing information does not document specific restrictions or dose adjustments based on hepatic (liver) or renal (kidney) function impairment.

Summary

Eligibility is primarily restricted by the absolute contraindication for hypersensitivity. Use is conditional for pregnant and nursing women, while safety is not established for the pediatric population. The medicine is generally for non-pregnant adult use, with specific cautionary requirements for women with recurrent infections or certain comorbidities.

Interactions with other medicines and products

The regulatory documentation for Butoconazole Cream emphasizes a physical-chemical interaction profile, with an absence of documented systemic drug-drug interactions. The minimal systemic absorption of the intravaginal formulation means that official labeling does not include information regarding metabolic (CYP), transporter, or pharmacodynamic interactions with other orally administered medicinal products.

Interaction Summary and Restrictions

The core documented constraint involves a component of the cream itself.

Interacting Entity	Interaction Type and Outcome	Mandatory Constraint
Mineral Oil (Excipient)	Documented to compromise the structural integrity of products made from latex or rubber.	Use of latex or rubber products must be avoided within the specified timeframe.
Latex or Rubber Devices	The physical-chemical incompatibility may lead to a reduction in the functional effectiveness of the barrier device.	The use of condoms or vaginal contraceptive diaphragms is restricted for 72 hours (three days) after the cream has been administered.

This official interaction structure is defined by the excipient's effect on material composition, establishing a required timing-based separation rule. This constraint must be observed to avoid the documented risk of compromised efficacy in the co-used barrier devices, as stated in government drug labels.

How Butoconazole Cream Works

Targeted Inhibition of Fungal Enzyme

Butoconazole acts at the molecular level by selectively inhibiting the fungal enzyme lanosterol 14-alpha demethylase ( CYP51), which is essential for fungal sterol metabolism. This inhibition of a specific metabolic step in the fungus is the primary mechanism that begins the process of cellular function impairment.

Disruption of Cell Membrane Integrity

The blockade of CYP51 prevents the fungus from synthesizing ergosterol, the key structural sterol of its cell membrane, leading to its critical depletion and the accumulation of toxic intermediate sterols. This mechanistic cascade results in the destabilization and increased permeability of the fungal cell membrane, which produces fungicidal activity (cell lysis) and fungistatic activity (inhibition of growth and replication).

Limitations of the Mechanism

The functional potential of this mechanism can be physiologically constrained by fungal resistance strategies. These include the upregulation of efflux pump proteins that actively transport the drug out of the fungal cell, or mutations in the CYP51 enzyme itself, both of which reduce the concentration of Butoconazole available at the target enzyme. The resulting local physiological effect is the cessation of fungal cellular expansion and compromise of survival viability.

Butoconazole Cream is administered through the intravaginal route using the single-use applicator provided. The medication is designated for local application and is not to be used orally or applied to external skin. The standard regimen for use involves a single dose, consisting of one full applicatorful, which corresponds to approximately five grams of the 2% cream, delivering 100 mg of Butoconazole Nitrate. This application is typically performed at bedtime to promote product retention.

While the primary use is a single administration, multi-day administration patterns are utilized for certain circumstances. An extended course of up to seven days (once daily) may be administered under medical supervision for specific patient populations, such as women in the second or third trimester of pregnancy, deviating from the standard single-dose pattern. Administration should continue even if the menstrual period occurs during the course.

Specific handling constraints apply to the use of this medication. The disposable applicator must be used to ensure the correct volume of cream is delivered. Furthermore, due to the presence of mineral oil in the formulation, which may compromise certain materials, the use of latex or rubber barrier contraceptive products, such as condoms or diaphragms, is restricted for at least 72 hours following treatment. Patients must also refrain from using tampons or douches during the course of therapy.

Evidence for Use in Vulvovaginal Candidiasis (VVC)

Research for Butoconazole Cream was studied for regulatory evaluation primarily through Randomized Controlled Trials (RCTs). These trials research examined what populations the research examined in a structured, investigator-blinded setting. VVC is a condition characterized by episodic manifestations caused by Candida yeast species. Studies often compared Butoconazole Cream against other treatments was observed in these research scenarios.

The main objective of the research was to monitor changes over defined time intervals. Findings data show patterns related to the resolution of signs and outcomes related to physical discomfort. Research also studied confirming the eradication of the fungal organism itself, which was defined as a core endpoint in VVC trials. These short-term trials followed a specific research scenario, generally studies conducted during periods of increased symptom activity.

Study Endpoints and Measured Outcomes

In these trials, researchers studies explored two key measures: Therapeutic Outcome Measurement and Microbiologic Eradication. The Therapeutic Outcome Measurement is a combined endpoint, defined in the research as the measurement of both a change in symptoms and the measured clearance of the Candida organism. Microbiologic Eradication is a distinct measure that requires specialized lab tests to confirm that the yeast is no longer present in the area studied. Research also studies monitored changes in patient-reported experiences related to physical discomfort over the course of the study. These outcomes research highlights changes measured during the study period and provide insight into the patterns observed in the studied populations.

Long-Term Studies and Observation Periods

The duration of follow-up in the core clinical trials for Butoconazole Cream was typically limited to the short term, generally assessing outcomes within 7 to 15 days after treatment. Researchers also studies monitored the study populations during an intermediate observation period, often around 30 days post-treatment, to evidence contributes to understanding symptom patterns related to potential reinfection or recurrence. Long-term data beyond this intermediate 30-day timeframe are not extensively characterized, meaning that long-term effects are not fully established in the available research.

Evidence in Specific Patient Populations

The research forming the basis of the regulatory was studied for results apply only to the populations studied, which were generally healthy adult women presenting with uncomplicated VVC. Data for certain groups remain insufficient because these populations were often excluded from the main trials. Specifically, the research profile for the medicine was not established in pregnant women during the pivotal research. Furthermore, the evidence is limited in providing insight for patients dealing with more complex VVC, such as individuals with recurrent infections or those with underlying systemic conditions.

Gaps and Uncertainties in the Research Record

A key limitation of the available research is the limited information for long-term outcomes beyond the initial and intermediate follow-up periods. While short-term changes were noted in some studies, the certainty remains low regarding the durability of these patterns over many months or years. Additionally, the sample sizes were modest in some studies, and evidence quality varies across studies. The current body of work research provides context but not individual predictions and highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

1. GYNAZOLE•1® Butoconazole Nitrate Vaginal Cream USP, 2% Label Information – DailyMed (NIH)

Common questions about Butoconazole Cream (FAQ)

---

Q: Is Butoconazole Cream an antibiotic or an antifungal medicine?

A: Official drug information clarifies that Butoconazole is classified as an azole antifungal medicine. This means its mechanism of action is specifically targeted toward fungal pathogens. It is not an antibiotic, which would target bacteria.

Q: Does Butoconazole Cream treat all types of fungal infections?

A: Regulatory documents state that this cream is specifically indicated for the local treatment of vulvovaginal candidiasis (a vaginal yeast infection). This condition is caused by Candida species. The official purpose is focused on this particular type of infection.

Q: Is Butoconazole Cream available over the counter (OTC) or only by prescription?

A: Official product information confirms that Butoconazole cream is supplied in both prescription and over-the-counter (OTC) formulations. These are used for the treatment of uncomplicated vaginal yeast infections.

Q: How quickly is Butoconazole Cream expected to start working?

A: Based on clinical trial data, the median time for patients to experience first relief of symptoms was reported to be approximately 17.5 hours after a single administration. This provides a general timeframe for when changes were first observed in studies.

Q: What should I do if I accidentally swallow some Butoconazole Cream?

A: If the cream is accidentally swallowed, the regulatory safety information advises contacting medical help or a Poison Control Center right away. The product is strictly for intravaginal use only.

Q: Does Butoconazole Cream come in different strengths?

A: According to the official FDA label, the product is supplied as Butoconazole Nitrate Vaginal Cream USP, 2%. This 2% concentration is the form used in the standard administration regimen.

Q: Is Butoconazole Cream effective for skin fungal infections (like ringworm)?

A: Official documents specify that the cream is for intravaginal administration only and must not be applied to external skin. Therefore, it is not the indicated product for treating conditions like ringworm or other skin fungal infections.

Q: How long does the effect of Butoconazole Cream typically last?

A: Research supporting the product’s use generally followed patients for resolution of the infection and symptoms over an intermediate period of up to 30 days post-treatment. This timeframe reflects the period of observation in clinical studies.

Q: Is there a generic version of Butoconazole Cream?

A: Yes, Butoconazole is available generically under its chemical name, Butoconazole Nitrate Vaginal Cream USP, 2%. It has also been available under a brand name.

Q: Can men use Butoconazole Cream for their symptoms?

A: Official labeling indicates the product is specifically for the treatment of vulvovaginal candidiasis in women. The indications for use do not cover the treatment of symptoms in men.

Q: What should I look for in the ingredients list besides the main active drug?

A: The official ingredients list includes inactive components, notably mineral oil. This ingredient is important because its presence necessitates the restriction on using latex or rubber products, such as condoms or diaphragms, during treatment.

Q: If I miss a dose, what does official information suggest doing?

A: Official instructions indicate that a missed dose may be inserted as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed dose should be skipped to continue with the regular schedule.

Q: Is Butoconazole Cream associated with a specific type of discharge or odor change?

A: The product’s intended purpose is to reduce symptoms like discharge caused by the yeast infection. Official safety information advises that unusual or foul-smelling vaginal discharge may be a sign of a more serious condition and may require evaluation by a healthcare provider.

Q: Can Butoconazole Cream interact with hormonal therapy?

A: Because the cream has minimal systemic absorption into the bloodstream, official labeling does not document systemic drug-drug interactions. Furthermore, official guidelines suggest disclosing all medications to a healthcare provider.

Q: Is Butoconazole Cream considered a high-risk drug based on regulatory classifications?

A: The regulatory status of the product for pregnant women is classified as Pregnancy Category C. This designation means that use is advised only if the potential benefit justifies the potential risk, as determined by a healthcare provider.

Q: Does official information clarify how Butoconazole Cream is absorbed into the body?

A: Pharmacokinetic studies documented in official information show that following a single vaginal administration, approximately 1.7% of the dose is absorbed into the body on average. This indicates the medication is primarily acting locally.

Q: Is Butoconazole Cream known by any other trade names internationally?

A: Yes, the active ingredient Butoconazole is also marketed under various trade names, including Gynazole-1®. These names are found in regulatory and prescribing information.

Q: Can I use Butoconazole Cream if I am allergic to other 'azole' antifungals?

A: Official patient labeling indicates the importance of disclosing to a healthcare provider if there is an allergy to Butoconazole or other azole antifungal agents. This is because hypersensitivity to any component of the cream is a contraindication for its use.

Q: Is Butoconazole Cream safe to use if I have diabetes?

A: Official safety information suggests the need for discussion with a healthcare provider if women experience frequent or recurrent vaginal yeast infections. This is to rule out a serious underlying medical cause, such as diabetes, which can affect infection recurrence.

Q: What are the general expectations if the symptoms don't clear up after use?

A: The product label indicates that stopping use and consulting a doctor is suggested if symptoms do not get better within 3 days or if they last for more than 7 days. This indicates the timeframe for expected relief.

Q: What is the significance of the concentration (e.g., 2%) in Butoconazole Cream?

A: Regulatory labeling shows that the concentration of 2% is formulated to deliver the specific therapeutic dose. The standard administration of one applicatorful of the 2% cream delivers approximately 100 mg of Butoconazole Nitrate.

Q: Does the efficacy of Butoconazole Cream depend on the specific strain of yeast?

A: Official microbiology information notes that the drug has demonstrated effectiveness against vaginal infections caused by Candida albicans. This is the most common yeast species responsible for this condition.

How to Store and Dispose of Butoconazole Cream

Official regulatory documentation defines precise rules for storing and discarding Butoconazole Cream to maintain product stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature Range	Store at 25 C (77 F) (Controlled Room Temperature), permitting excursions from 15 C to 30 C.
Protection	Do not freeze and avoid exposure to excess heat and moisture.
Container Rule	Keep the medication in the original container and ensure it is tightly closed at all times.
Child Safety	The product must be stored out of the reach of children.

Disposal Instructions

Expired or unused Butoconazole Cream must be discarded according to official guidelines. The preferred method is to utilize a medicine take-back program. If this option is unavailable, the cream should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed bag or container, and disposed of in the household trash. It is explicitly instructed not to flush the cream down the toilet or pour it down the sink.